2015 Volume 108 Issue 9 Pages 713-718
Background:
Concurrent chemoradiotherapy is one of the standard treatment for locally advanced head and neck cancer. Cisplatin is the most feasible regimen of concurrent chemoradiotherapy. However the clinical response has been less satisfactory favorable.
The favorable efficacy of chemotherapy with cisplatin and docetaxel, 5-FU (TPF) as induction chemotherapy for head and neck cancer have been reported. However the feasibility of concurrent chemoradiotherapy with TPF has been sparsely reported and has had many limitations. The purpose of this study was to identify the feasibility of TPF concurrent chemoradiotherapy.
Materials & Methods:
We retrospectively analyzed 60 head and neck cancer patients treated with definitive concurrent TPF chemoradiotherapy. We investigated the treatment completion rate, adverse events, average relative dose intensity, and causes of dose reduction.
Results:
The treatment completion rate was 98.3% and ARDI was 70%. Hematological adverse events over Grade 3 were observed as leukopenia 60.9%, neutropenia 60%, anemia 11.8%, and thrombocytopenia 6.4%. Febrile neutropenia was observed as 16.4% patients however no treatment related death was observed.
Conclusion:
Concurrent chemoradiotherapy with TPF was a feasible treatment for head neck cancer. We should continuously investigate the efficacy of this treatment.
